Loading…
Reported covered position: Hon. Larry Bucshon - Chief of Staff, Senator Elizabeth Dole - Legislative Director--Hon. Patrick McHenry - Chief of Staff---Hon. Robin Hayes - Legislative Senator , Hon. Jesse Helms - Hon, Howard Coble
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
Mikaela Naylon Give Kids a Chance Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Trade-related public policy around tariffs and intellectual property, no related bills
Source: Senate LDA
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies and affordability Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Accelerating Access to Dementia and Alzheimer’s Provider Training Act
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Accelerating Access to Dementia and Alzheimer’s Provider Training Act
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
Accelerating Access to Dementia and Alzheimer’s Provider Training Act
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies and affordability Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies and affordability Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Issues related to H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. ORPHAN CURES Act, no current bill number Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Issues related to H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. ORPHAN CURES Act, no current bill number Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Issues related to H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. ORPHAN CURES Act, no current bill number Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Discussions related to H.R.1, One Big Beautiful Bill Act (2025) Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act S.3558, BioSecure Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Prohibiting Foreign Access to American Genetic Information Act of 2024
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act S.3558, BioSecure Act
Prohibiting Foreign Access to American Genetic Information Act of 2024
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Prohibiting Foreign Access to American Genetic Information Act of 2024
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Prohibiting Foreign Access to American Genetic Information Act of 2024
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.127, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to tax CMS/NCD draft decision on monoclonal antibodies
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies and affordability Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Trade-related public policy around tariffs and intellectual property, no related bills
Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Trade-related public policy around tariffs and intellectual property, no related bills
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill.
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill.
Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Trade-related public policy around tariffs and intellectual property, no related bills
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Issues related to H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. ORPHAN CURES Act, no current bill number Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA), White House Office
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill.
Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B progran, no specific bill.
Trade-related public policy around tariffs and intellectual property, no related bills
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B progran, no specific bill.
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B progran, no specific bill. Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
Issues related to the 340B program reforms
Support stronger IP and exclusivity protections and enforcement in foreign markets Biopharmaceutical innovation and patent policy Bayh-Dole March-in rights, Patent thicket, and AI policy issues
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Support stronger IP and exclusivity protections and enforcement in foreign markets Biopharmaceutical innovation and patent policy Bayh-Dole March-in rights, Patent thicket, and AI policy issues
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Support stronger IP and exclusivity protections and enforcement in foreign markets
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act S.3558, BioSecure Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovation and Jobs Act Issues related to OECD negotiations on the taxation of global income
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy issues Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments Issues related to the 340B program Medicare reform
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovation and Jobs Act Issues related to OECD negotiations on the taxation of global income
Appropriations on mental health and Alzheiner's screening and diagnosis
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) Research and Development Tax Credit American Innovation and Jobs Act Tax Provisions of Budget Reconciliation
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation, including provisions related to corporate taxes, Medicare, and prescription drug pricing Mental Health Workforce Expansion The Mental Health Professionals Workforce Shortage Loan Repayment Act HELP Copays Act Issues related to ALS
H.R.4373, Further Additional Continuing Appropriations and Extensions Act, 2023
Drug cost and pricing policy Patient affordability issues policy proposals related to clinical trial diversity Issues related to the 340B program
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to tax CMS/NCD draft decision on monoclonal antibodies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act
IP/Trade TRIPS Waiver
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
S.Con.Res.14, FY 2022 Congressional Budget
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product
IP/Trade TRIPS Waiver
IP/Trade TRIPS Waiver
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Discussions regarding H.R. 1319, the American Rescue Plan S.1427/H.R.2869, Increasing Access to Biosimilars Act of 2021 H.R.2815, Bolstering Innovative Options to Save Immediately on Medisines (BIOSIM) Act H.R.2855, Star Rating for Biosimilars
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Education and discussions regarding pharmaceutical issues related to supply chain
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Discussions regarding H.R. 1319, the American Rescue Plan Discussions regarding Zero co-payment for biosimilars Discussions regarding Biogen's Healthy Climate, Healthy Lives initiative Issues related to the CHANGE Act Vial size wastage issue
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129)
Discussions regarding H.R.133, the Consolidated Appropriations Act of 2021
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Discussions regarding S.4295, Public Helath Emergency Pass-Through Payment Fairness Act of 2020
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Discussions regarding Executive Orders, Most Favored Nation-Importation Discussions regarding pass-throughs Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues
Discussions regarding Medicaid 340B drug discount program Support for legislation H.R.4597/S.3466 instituting 0$ co-pay for biosimilars under Medicare Discussions regarding pass-through status of Spinraza
Discussions regarding rare diseases, drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Support for H.R.3772, Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act), supported 90-day prescription drug supply (Sec.3714) H.R.1425, the Patient Protection and Affordable Care Enhancement Act, drug pricing provisions S.4049/H.R.6395, National Defense Authorization Act for Fiscal Year 2021 (Supply chain and Tricare pharmacy pilot program) Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Discussions regarding Medicaid 340B drug discount program
Discussions regarding rare diseases, Alzheimer's policy, drug pricing, PET scan coverage and reimbursement, and dementia care H.R.3772 - Alzheimers Diagnosis with PET Appropriations on Alzheimers screening and diagnosis study Discussions regarding Part B home infusion during Covid-19 crisis H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 H.R.6201 - Families First Coronavirus Response Act H.R.748 - Coronavirus Aid, Relief, and Economic Security Act (CARES Act)
Discussions regarding pharmaceutical issues related to supply chain Kingdom of Saudi Arabia issue related to pharmaceuticals H.R.3, Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2019 S.2543, Prescription Drug Pricing Reduction Act of 2019
1. The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 (entire bill) -- 2. H.R. 3, Lower Drug Costs Now Act of 2019 (entire bill 3. Biosimilars Policy (no Bill). Advocacy for policy supporting/ that will spur the entry of biosimilars into the United States that will provide the Headroom for Innovation and is additive to the drug pricing policy debate. 4. Prescription Pricing for People Act (S. 1227/H.R. 2376) -SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER ACTIVITY as it pertains to PBMS and the supply chain. 5. Drug Rebate regulation - (no Bill) -Discussion regarding the Administrations withdrawal Harmful Drug Rebate Safe Harbor Rule, CBO Estimates, 6. Issues related to state based Newborn Screening Programs and tests (no Bill) 7. S.2543 - Prescription Drug Pricing Reduction Act of 2019
S.1416 - Affordable Prescriptions for Patients Act of 2019 pertaining to the U.S. Patent system and well as patent law as it pertains to the IP system/process.SEC. 106. RESTORATION OF PATENTS AS PROPERTY RIGHTS. Entire Bill with particular emphasis on Secti 2, product hoping and patent thickening
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws.
Discussions related to H.R.1, One Big Beautiful Bill Act (2025) Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Trade-related public policy around tariffs and intellectual property, no related bills
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
General issues related to the manufacturing workforce
Trade-related public policy around tariffs and intellectual property, no related bills
Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Support stronger IP and exclusivity protections and enforcement in foreign markets Biopharmaceutical innovation and patent policy Bayh-Dole March-in rights, Patent thicket, and AI policy issues
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Support stronger IP and exclusivity protections and enforcement in foreign markets Biopharmaceutical innovation and patent policy Bayh-Dole March-in rights, Patent thicket, and AI policy issues
Issues related to the 340B program reforms
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Issues related to the 340B program reforms
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to the 340B program reforms
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Drug cost and pricing policy issues Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments Issues related to the 340B program Medicare reform
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Appropriations on mental health and Alzheiner's screening and diagnosis
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Drug cost and pricing policy issues Issues related to the 340B program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Drug cost and pricing policy issues Issues related to the 340B program
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovation and Jobs Act Issues related to OECD negotiations on the taxation of global income
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Drug cost and pricing policy S.127, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis H.R.19, Lower Costs, More Cures Act of 2021 Discussions regarding FDA approval of Aduhelm
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding H.Con.Res. 11, FY2021 Budget Resolution
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Support for H.R.1520/S.1895 codifying the Purple Book Discussions regarding S.2546/H.R.2279, the Safe Step Act, patient access issues Support for H.R.6179 directing CMS to implement a shared savings model for biosimilars
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Education and discussions regarding pharmaceutical issues related to supply chain H.R.3, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package Discussions regarding support for H.R.3991/S.1416 limiting the number of certain patents of biologics reference product Oppose drug pricing proposals that include international pricing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19, S.3129)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Issues related to changes in the Medicare Part B reimbursement system; issues related to changes in Iternational Pricing Index proposal; and Administration and Congressional proposal to address rebates in the Medicare Part D program the Prescription Drug Pricing Reduction Act (PDPRA) of 2019 andH.R. 3, Lower Drug Costs Now Act of 2019).
IP protections for biologics and pharmaceuticals, consistent with U.S. law, to be included in trade agreements.
Corporate tax requirements and jobs: Domestic and international tax policies that protect and incentivize U.S. based research and manufacturing jobs including the net cost of Biogen R & D and well as percentage of revenue spent on R &D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE